3 March 2015BiotechnologyLaura von Hertzen and Robert Burrows
Stem cells: A germ of comfort
Stem cell research is advancing at an incredibly fast pace. Technology based on the use of human embryonic stem cells (hESCs) is being employed in an attempt to tackle a wide variety of conditions including vision loss, diabetes, heart disease and skin disorders. However, with such cutting-edge research comes moral considerations, which in turn have implications for the type of technology that
is patentable.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
25 June 2026 Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines.
22 June 2026 The partnership, announced at BIO 2026, marks the largest Asia-Pacific partnership by potential value that the AI-driven drug discovery company has secured to date.
4 June 2026 The deal gives Pfizer access to 12 early-stage oncology programmes and marks the latest in a growing wave of high-value licensing agreements between Big Pharma and Chinese biotechs.